BCIQ Profiles

Company Profile Report

Cold Harbor JV developing copper chelator for Wilson's disease

DepYmed Inc., a joint venture between Cold Spring Harbor Laboratory and Ohr Pharmaceutical Inc. (NASDAQ:OHRP), is developing its protein tyrosine phosphatase 1B (PTP-1B; PTPN1) inhibitor DPM-1001 as a copper chelator for Wilson's disease. In a Genes & Development study, Cold Spring Harbor researchers showed

Read the full 444 word article

How to gain access

Continue reading with a
two-week free trial.